Johnson & Johnson (NYSE: JNJ), a multinational healthcare conglomerate based in the US, has announced a definitive agreement to acquire V-Wave Ltd, an innovative Israeli medical device developer. The acquisition includes an initial payment of USD 600 million, with additional potential payments of up to USD 1.1 billion tied to regulatory and commercial milestones. The transaction is anticipated to be finalized in the fourth quarter of 2024, with V-Wave integrating into J&J MedTech. Michael Bodner, J&J’s group president overseeing heart recovery and intravascular lithotripsy, will assume leadership of V-Wave post-acquisition.
Founded in 2009, V-Wave has dedicated itself to the advancement of medical devices catering to individuals with heart failure and other cardiovascular diseases (CVDs). The company’s flagship product is the Ventura Interatrial Shunt (IAS), a novel cardiovascular implant intended for patients afflicted with heart failure with reduced ejection fraction (HFrEF). The IAS is inserted through a minimally invasive catheter-based procedure and functions by creating a shunt between the left and right atrium, thereby reducing elevated left atrial pressure associated with congestive heart failure. This innovative approach aims to decrease the incidence of cardiovascular events and hospitalizations due to heart failure. The IAS received a breakthrough device designation from the US FDA in 2019 and obtained the CE mark in 2020, marking a significant milestone in its development and potential impact on patient care.- Flcube.com
